Cargando…

Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient

BACKGROUND: Human cytomegalovirus infections are still significant causes of morbidity and mortality in transplant recipients. The use of antiviral agents is limited by toxicity and evolving resistance in immunocompromised patients with ongoing viral replication during therapy. Here, we present the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schubert, Axel, Ehlert, Karoline, Schuler-Luettmann, Susanne, Gentner, Eva, Mertens, Thomas, Michel, Detlef
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3720178/ https://www.ncbi.nlm.nih.gov/pubmed/23870704 http://dx.doi.org/10.1186/1471-2334-13-330

Ejemplares similares

Evaluating the Safety of Maribavir for the Treatment of Cytomegalovirus
por: Gandhi, Ronak G, et al.
Publicado: (2022)

Late HBsAg seroreversion of mutated hepatitis B virus after bone marrow transplantation
por: Schubert, Axel, et al.
Publicado: (2013)

Maribavir for Cytomegalovirus Treatment in the Real World—Not a Silver Bullet
por: Fung, Monica, et al.
Publicado: (2022)

Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient
por: Jung, Susanne, et al.
Publicado: (2019)

The effects of maribavir on the autophosphorylation of ganciclovir resistant mutants of the cytomegalovirus UL97 protein
por: Shannon-Lowe, Claire D, et al.
Publicado: (2010)

Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study
por: Papanicolaou, Genovefa A, et al.
Publicado: (2019)

21. Efficacy and Safety of Maribavir as a Rescue Treatment for Investigator Assigned Therapy in Transplant Recipients With Refractory or Resistant Cytomegalovirus Infections in the SOLSTICE Study: Phase 3 Trial Results
por: Pereira, Marcus, et al.
Publicado: (2021)

Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection
por: Chou, Sunwen, et al.
Publicado: (2020)

Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial( )
por: Avery, Robin K, et al.
Publicado: (2021)

Correction to: Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial
Publicado: (2023)

Detection of Low Frequency Multi-Drug Resistance and Novel Putative Maribavir Resistance in Immunocompromised Pediatric Patients with Cytomegalovirus
por: Houldcroft, Charlotte J., et al.
Publicado: (2016)

Population pharmacokinetic modeling and simulation of maribavir to support dose selection and regulatory approval in adolescents with posttransplant refractory cytomegalovirus
por: Sun, Kefeng, et al.
Publicado: (2023)

Cytomegalovirus infection in transplant recipients
por: Azevedo*, Luiz Sergio, et al.
Publicado: (2015)

Synthesis of New Imidazopyridine Nucleoside Derivatives Designed as Maribavir Analogues
por: Papadakis, Georgios, et al.
Publicado: (2020)

Conserved retinoblastoma protein-binding motif in human cytomegalovirus UL97 kinase minimally impacts viral replication but affects susceptibility to maribavir
por: Gill, Rachel B, et al.
Publicado: (2009)

Placental transfer of Letermovir & Maribavir in the ex vivo human cotyledon perfusion model. New perspectives for in utero treatment of congenital cytomegalovirus infection
por: Faure Bardon, Valentine, et al.
Publicado: (2020)

Holoendemic cytomegalovirus infection in renal transplant recipients.
por: Fiala, M., et al.
Publicado: (1976)

Effects of Maribavir on P‐Glycoprotein and CYP2D6 in Healthy Volunteers
por: Song, Ivy H., et al.
Publicado: (2019)

Evaluation of the Effect of Maribavir on Cardiac Repolarization in Healthy Participants: Thorough QT/QTc Study
por: Ilic, Katarina, et al.
Publicado: (2020)

S294: MARIBAVIR (MBV) VERSUS INVESTIGATOR-ASSIGNED THERAPY FOR REFRACTORY CYTOMEGALOVIRUS (CMV) INFECTION: SUBGROUPS ANALYSES OF PHASE 3 STUDY BY RESISTANCE STATUS KNOWLEDGE REPORTED BY INVESTIGATORS.
por: Duarte, Rafael F, et al.
Publicado: (2023)

Cytomegalovirus –The Quest for an Effective Vaccine in Transplant Recipients Continues
por: Boeckh, Michael, et al.
Publicado: (2015)

Mucormycosis and Cytomegalovirus Co-infection in Renal Transplant Recipients
por: Gupta, K. L.
Publicado: (2017)

Viral Pneumonias Other Than Cytomegalovirus in Transplant Recipients
por: Barton, Todd D., et al.
Publicado: (2005)

Cytomegalovirus-Specific T Cells in Pediatric Liver Transplant Recipients
por: Getsuwan, Songpon, et al.
Publicado: (2023)

Multiorgan WU Polyomavirus Infection in Bone Marrow Transplant Recipient
por: Siebrasse, Erica A., et al.
Publicado: (2016)

Diarrhea in pediatric recipients of solid organ or bone marrow transplants
por: Phrommas, Jirachart, et al.
Publicado: (2021)

Hemophagocytic Syndrome with Bone Marrow Tuberculosis in Renal Transplant Recipient
por: Das, Sukanto K., et al.
Publicado: (2022)

Successful Treatment with Ganciclovir for Cytomegalovirus Duodenitis following Allogenic Bone Marrow Transplantation
por: Ahn, Jin Hee, et al.
Publicado: (1999)

Cytomegalovirus Viremia in Renal Transplant Recipients After Influenza Vaccination
por: Khatri, Akshay M, et al.
Publicado: (2020)

Cytomegalovirus-Induced Adrenal Insufficiency in a Renal Transplant Recipient
por: Ardalan, M., et al.
Publicado: (2009)

Cytomegalovirus monitoring in allogeneic haemopoietic stem cell transplant recipients
por: Ramalingam, S., et al.
Publicado: (2006)

1109. Valgancyclovir Dosing for Cytomegalovirus Prophylaxis in Heart Transplant Recipients
por: Huang, Glen, et al.
Publicado: (2020)

Thrombosis Associated With Cytomegalovirus (CMV) in a Kidney Transplant Recipient
por: Wang, Lin, et al.
Publicado: (2021)

Cytomegalovirus drug resistance mutations in transplant recipients with suspected resistance
por: Recio, Vanessa, et al.
Publicado: (2023)

Genomic Markers Associated with Cytomegalovirus DNAemia in Kidney Transplant Recipients
por: Shapira, Guy, et al.
Publicado: (2023)

De Novo Cytomegalovirus Colitis in a Donor-Seronegative/Recipient-Seronegative Kidney Transplant Recipient
por: Sulaiman, Zoheb I, et al.
Publicado: (2023)

QuantiFERON-Cytomegalovirus Assay for Prediction of Cytomegalovirus Viremia in Kidney Transplant Recipients: Study From High Cytomegalovirus Seroprevalence Country
por: Pongsakornkullachart, Kritsada, et al.
Publicado: (2022)

Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients
por: Deborska-Materkowska, Dominika, et al.
Publicado: (2018)

Bilateral Toxoplasma Retinochoroiditis Simulating Cytomegalovirus Retinitis in an Allogeneic Bone Marrow Transplant Patient
por: Chung, Hyewon, et al.
Publicado: (2008)

Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients
por: Egli, Adrian, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_09dgrij91107eq229v72piooih